This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Famicordtx S.A. announced that it has received €3.5 million in funding from NextCell Pharma AB, Polski Bank Komórek Macierzystych S.A. and other investors CI
VITA 34 AG completed the acquisition of Polski Bank Komórek Macierzystych S.A from from AOC Health GmbH, Jakub Baran, Tomasz Baran and others. CI
Polski Bank Kom?rek Macierzystych S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Vita 34 : Commences Offer Period for Polski Bank Komorek Takeover MT
Polski Bank Komórek Macierzystych S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Polski Bank Komórek Macierzystych S.A. announced that it expects to receive PLN 0.01724 million in funding CI
Polski Bank Komórek Macierzystych S A : Ominvest Receives Watchdog Approval To Increase Stake In Bank Muscat MT
NextCell Pharma AB Enters CAR-T Joint Venture CI
Vita 34 : Polski Bank Komorek Agree To Merge Via Share Swap MT
VITA 34 AG entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million. CI
Polski Bank Komórek Macierzystych S.A. agreed to acquire 80% stake in Smart Cells Holdings Limited for PLN 21.1 million. CI
Polski Bank Komórek Macierzystych S.A. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Polski Bank Komórek Macierzystych S.A. completed the acquisition of 26% stake in Rodinná Banka Perinatálnych a Mezenchymálnych Buniek. CI
Polski Bank Komórek Macierzystych S.A. completed the acquisition of 53% stake in Sorgente Srl from Roberto Maranin, Salvatore Iuzzolini and Emiliano Gummati. CI
Polski Bank Komórek Macierzystych S.A. completed the acquisition of eticur) GmbH from InGeneron, Inc. and others. CI
Polski Bank Komórek Macierzystych S.A. signed preliminary share purchase agreement to acquire eticur) GmbH from InGeneron, Inc. and others for €2.5 million. CI
Polski Bank Komórek Macierzystych S.A. signed preliminary agreement to acquire 53% stake in Sorgente Srl from Roberto Maranin, Salvatore Iuzzolini and Emiliano Gummati for €0.42 million. CI
Polski Bank Komórek Macierzystych S.A. Reports Revenue Results for the Year 2019 CI
Polski Bank Komórek Macierzystych S.A. acquired 70% stake in Famicord - Acibadem from Acibadem Saglik Hizmetleri ve Ticaret Anonim Sirketi for PLN 12.9 million. CI
Active Ownership Fund SCS FIS SCS, managed by Active Ownership Capital S.à.r.lcompleted the acquisition of 10.6% stake in Polski Bank Komórek Macierzystych S.A. from AOC Health GmbH. CI
Active Ownership Fund SCS FIS SCS, managed by Active Ownership Capital S.à.r.l. made a tender offer to acquire 10.6% stake in Polski Bank Komórek Macierzystych S.A. from AOC Health GmbH for PLN 64.8 million. CI
Platin 1829. GmbH entered into an agreement to acquire unknown minority stake in Polski Bank Komórek Macierzystych S.A. (WSE : BKM). CI
Polski Bank Komórek Macierzystych S.A. Reports Consolidated and Parent Earnings Results for the Third Quarter and Nine Months Ended September 30, 2019 CI
Polski Bank Komórek Macierzystych S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Esperite Resumes Takeover Talks With Polski Bank Komorek Business CI
Chart POLI BANK
More charts
Polski Bank Komorek Macierzystych SA (PBKM) is a Poland-based company that carries out full set of researches from umbilical cord blood. PBKM is the cord blood bank in Poland, which is one of public and private cord banks in Europe accredited by American Association of Blood Banks (AABB). The Company cooperates with the Institute of Human Genetics PAS (Polish Academy of Sciences), Medicover, LUX MED Salus Clinic, Medical Centers Salve, as well as Falck Sp z o o and Alab Laboratories, among others. The public cord blood bank aims to increase the resources of the stored cord blood and the use of cord blood for transplantation in Poland. The Company forms a part of the international group of banks of stem cells from umbilical cord blood, FamiCord, which consists of laboratories in Poland, Hungary, Romania, Spain and Turkey, and which collaborates with over 1100 hospitals throughout Europe.
More about the company
  1. Stock Market
  2. Equities
  3. BKM Stock
  4. News POLI BANK
  5. Polski Bank Komórek Macierzystych S A : Ominvest Receives Watchdog Approval To Increase Stake In Bank Muscat